BACKGROUND: Alterations in apoptosis and DNA damage repair related proteins are associated with resistance to chemotherapy, which is the most important cause of treatment failure in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Pretreatment tumor biopsy specimens from 50 patients with NSCLC including stage IIIB with malignant pleural effusion or stage IV or recurrent disease were analyzed for p53, Bcl-2, Bax, and ERCC1 expression by immunohistochemistry. All patients were treated with platinum-based third-generation doublet chemotherapy, in which gemcitabine and cisplatin was the most commonly administered regimen (17 patients). RESULTS: High expression of p53, Bcl-2, Bax, and ERCC1 was observed in 24 (48%), 8 (16%), 32 (63%), and 28 (55%) patients, respectively. In univariate analysis, high expression of ERCC1 demonstrated a trend of association with poor overall survival (OS) (median, 8 months vs. 11 months; P=0.055). High expression of p53, Bcl-2, Bax was not correlated with patient outcome. High expression of ERCC1 was an independent prognostic factor for poor OS (P=0.002) along with poor performance status (P=0.028) and lack of disease control (P=0.001) in multivariate analysis. CONCLUSIONS: High expression of ERCC1 may be a useful prognostic factor for poor outcome in advanced NSCLC patients treated with platinum and third-generation doublet chemotherapy.
BACKGROUND: Alterations in apoptosis and DNA damage repair related proteins are associated with resistance to chemotherapy, which is the most important cause of treatment failure in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Pretreatment tumor biopsy specimens from 50 patients with NSCLC including stage IIIB with malignant pleural effusion or stage IV or recurrent disease were analyzed for p53, Bcl-2, Bax, and ERCC1 expression by immunohistochemistry. All patients were treated with platinum-based third-generation doublet chemotherapy, in which gemcitabine and cisplatin was the most commonly administered regimen (17 patients). RESULTS: High expression of p53, Bcl-2, Bax, and ERCC1 was observed in 24 (48%), 8 (16%), 32 (63%), and 28 (55%) patients, respectively. In univariate analysis, high expression of ERCC1 demonstrated a trend of association with poor overall survival (OS) (median, 8 months vs. 11 months; P=0.055). High expression of p53, Bcl-2, Bax was not correlated with patient outcome. High expression of ERCC1 was an independent prognostic factor for poor OS (P=0.002) along with poor performance status (P=0.028) and lack of disease control (P=0.001) in multivariate analysis. CONCLUSIONS: High expression of ERCC1 may be a useful prognostic factor for poor outcome in advanced NSCLCpatients treated with platinum and third-generation doublet chemotherapy.
Authors: Kimberly Johung; Amar Rewari; Hao Wu; Benjamin Judson; Joseph N Contessa; Bruce G Haffty; Roy H Decker Journal: Head Neck Date: 2012-06-28 Impact factor: 3.147
Authors: Matthias Villalobos; Piotr Czapiewski; Niels Reinmuth; Jürgen R Fischer; Stefan Andreas; Cornelius Kortsik; Monika Serke; Martin Wolf; Petra Neuser; Alexander Reuss; Philipp A Schnabel; Michael Thomas Journal: Med Oncol Date: 2018-06-15 Impact factor: 3.064
Authors: Valsamo K Anagnostou; Frank J Lowery; Vassiliki Zolota; Vassiliki Tzelepi; Arun Gopinath; Camil Liceaga; Nikolaos Panagopoulos; Konstantina Frangia; Lynn Tanoue; Daniel Boffa; Scott Gettinger; Frank Detterbeck; Robert J Homer; Dimitrios Dougenis; David L Rimm; Konstantinos N Syrigos Journal: BMC Cancer Date: 2010-05-09 Impact factor: 4.430